Skip to content
HowShorted

Allogene Therapeutics, Inc. short interest in 2022

In 2022, Allogene Therapeutics, Inc.'s disclosed short interest ran from 6.37% of shares outstanding on 14 Jan 2022 to 23.18% on 30 Dec 2022, a change of +16.81 percentage points. The year's high was 23.18% on 30 Dec 2022 and its low 6.37% on 14 Jan 2022, averaging 14.96% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 23.85 days on 31 Oct 2022. Full history: Allogene Therapeutics, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Allogene Therapeutics, Inc. in 2022

2022 in figures

Start of year
6.37% (14 Jan 2022)
End of year
23.18% (30 Dec 2022)
Change
+16.81 pp
High
23.18% (30 Dec 2022)
Low
6.37% (14 Jan 2022)
Average
14.96%
Highest days to cover
23.85 (31 Oct 2022)
SEC filings marked
8

Every report in 2022

Allogene Therapeutics, Inc. short interest in 2022
SettlementShort interestDays to coverFilings since previous
14 Jan 20226.37%4.52
31 Jan 20226.69%4.97
15 Feb 20227.36%9.53
28 Feb 20228.59%6.7110-K filed, results (8-K)
15 Mar 202210.20%9.68
31 Mar 202210.69%7.82
14 Apr 202212.68%13.42
29 Apr 202212.46%8.84
13 May 202212.32%7.1910-Q filed, results (8-K)
31 May 202214.03%12.81
15 Jun 202215.36%10.35
30 Jun 202215.66%6.93
15 Jul 202215.62%11.33
29 Jul 202215.60%18.68
15 Aug 202215.69%12.0810-Q filed, results (8-K)
31 Aug 202215.31%19.44
15 Sep 202215.45%15.06
30 Sep 202219.18%10.87
14 Oct 202220.90%16.94
31 Oct 202221.47%23.85
15 Nov 202221.81%17.0810-Q filed, results (8-K)
30 Nov 202221.13%14.52
15 Dec 202221.17%17.49
30 Dec 202223.18%15.59

See also: Allogene Therapeutics, Inc.'s full history · most shorted US stocks of 2022 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.